Institutional members access full text with Ovid®

Share this article on:

Effects of Autologous Platelet-Rich Plasma on Cell Viability and Collagen Synthesis in Injured Human Anterior Cruciate Ligament

Fallouh, Louay MD, PhD; Nakagawa, Koichi MD, PhD; Sasho, Takahisa MD, PhD; Arai, Momoko ME; Kitahara, Sota MD, PhD; Wada, Yuichi MD, PhD; Moriya, Hideshige MD, PhD; Takahashi, Kazuhisa MD, PhD

Journal of Bone & Joint Surgery - American Volume: 15 December 2010 - Volume 92 - Issue 18 - p 2909–2916
doi: 10.2106/JBJS.I.01158
Scientific Articles

Background: Platelet-rich plasma is a fraction of plasma in which platelets are concentrated. It is reported to represent a source of multiple growth factors that promote tissue repair. In anticipation of the eventual testing of platelet-rich plasma in anterior cruciate ligament (ACL)-deficient patients, we examined the effect of autologous platelet-rich plasma on human ACL cell function in vitro.

Methods: Fresh blood and ACL remnants were obtained from four patients who underwent ACL reconstruction surgery. Platelet-poor plasma and platelet-rich plasma were prepared from the blood samples. The concentrations of various growth factors in each preparation were tested with use of enzyme-linked immunosorbent assays. Isolated ACL cells were cultured in the presence of 5% fetal bovine serum, 5% platelet-poor clot releasate, 5% platelet-rich clot releasate, or 10% platelet-rich clot releasate. Platelet-rich plasma and platelet-poor plasma releasates were applied to the ACL cells from the same patient autologously. Cell viability and collagen synthesis in each group were analyzed, and semiquantitative gene-expression assays for type-I and III collagen were also performed.

Results: The concentrations of the main growth factors (transforming growth factor-beta, platelet-derived growth factor, epidermal growth factor, and vascular endothelial growth factor) were much higher in platelet-rich clot releasate than in platelet-poor clot releasate. In vitro treatment of ACL cells with platelet-rich clot releasate resulted in a significant increase in cell number compared with platelet-poor clot releasate. Total collagen production by the platelet-rich clot releasate-treated cells was significantly higher than that of the platelet-poor clot releasate-treated cells only because of enhanced cell proliferation. There was no significant effect of platelet-rich clot releasate treatment on gene expression for type-I collagen, but expression of type-III collagen was significantly enhanced by the treatment with platelet-rich clot releasate.

Conclusions: These results suggest that autologous platelet-rich plasma can enhance ACL cell viability and function in vitro.

1Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

2Department of Orthopaedic Surgery, Sakura Medical Center, Toho University, 564-1 Shimoshizu, Sakura, Chiba 285-8741, Japan. E-mail address: konakag@aol.com

3Department of Orthopaedic Surgery, Chiba Medical Center, Teikyo University, 3426-3 Anegasaki, Ichihara 299-0111, Japan

Copyright 2010 by The Journal of Bone and Joint Surgery, Incorporated
You currently do not have access to this article

To access this article: